Catalog No.
DHB95801
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
IL2-RA, IL-2R subunit alpha, TAC antigen, IL-2-RA, p55, IL2RA, IL-2 receptor subunit alpha, Interleukin-2 receptor subunit alpha, CD25
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01589
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BIIB019, DAC HYP, CAS: 152923-56-3
Clone ID
Daclizumab
Daclizumab Therapy for Multiple Sclerosis, PMID: 29661806
Daclizumab in multiple sclerosis, PMID: 29645071
▼ Daclizumab for MS, PMID: 28183723
Daclizumab, PMID: 17916050
Daclizumab: A Review in Relapsing Multiple Sclerosis, PMID: 28211007
Daclizumab for the treatment of multiple sclerosis, PMID: 28849702
Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis, PMID: 28803486
Daclizumab therapy for multiple sclerosis, PMID: 23055048
Daclizumab-induced encephalitis in multiple sclerosis, PMID: 31549941
Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis, PMID: 28707278
Daclizumab and its use in multiple sclerosis treatment, PMID: 28387383
Daclizumab for relapsing remitting multiple sclerosis, PMID: 22513956
Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis, PMID: 29363337
Daclizumab for relapsing remitting multiple sclerosis, PMID: 24363032
Daclizumab for relapsing remitting multiple sclerosis, PMID: 20556791
Daclizumab (anti-CD25) in multiple sclerosis, PMID: 24768797
Daclizumab: a review of its use in the management of organ transplantation, PMID: 11707149
Daclizumab: a potential asthma therapy?, PMID: 20804450
Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma, PMID: 17530023
Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients, PMID: 10651389
Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis, PMID: 23732529
Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry, PMID: 32391016
Immune-mediated encephalitis with daclizumab: The final nail, PMID: 30073908
End of the road for daclizumab in multiple sclerosis, PMID: 29565004
Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis, PMID: 30657420
A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis, PMID: 25826609
Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis, PMID: 24143075
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study, PMID: 32451615
Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis, PMID: 22284868
Daclizumab for the treatment of relapsing-remitting multiple sclerosis, PMID: 28286970
Daclizumab to prevent rejection after cardiac transplantation, PMID: 15987919
90 Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma, PMID: 32275165
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis, PMID: 26444729
A fatal case of daclizumab-induced liver failure in a patient with MS, PMID: 30800722
Daclizumab (Zinbryta) for multiple sclerosis, PMID: 27603962
The development of sarcoidosis in patients receiving daclizumab: A case series from multiple clinical trials, PMID: 30885425
Disease modifying therapies for relapsing multiple sclerosis, PMID: 27549763
Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab, PMID: 11522853
Daclizumab use in patients with pediatric multiple sclerosis, PMID: 22232346
Rash developing after cessation of Daclizumab for relapsing remitting MS; a case series, PMID: 31421627
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis, PMID: 24532277
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial, PMID: 23562009
Severe cutaneous adverse event in a daclizumab-treated multiple sclerosis patient, PMID: 31228714
Delayed onset hypophysitis after therapy with daclizumab for multiple sclerosis - A report of two cases, PMID: 33387829
Daclizumab induction therapy in liver transplant recipients with renal insufficiency, PMID: 20659283
Daclizumab for treatment of birdshot chorioretinopathy, PMID: 18268208
[Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab], PMID: 18206084
Spotlight on anti-CD25: daclizumab in MS, PMID: 18808743
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial, PMID: 24656609
A case of immune-mediated encephalitis related to daclizumab therapy, PMID: 30073905
For research use only. Not for human or drug use.
